Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOK | Q9UQ07 | 11/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.60 |
| ▸ | RAD52 | P43351 | 1/20 | 0.59 |
| ▸ | UBE2N | P61088 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970873 | 0.89 | MOK (0.80) | MOKKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL19508617 | 0.87 | MOK (1.00) | MOKKMT2AMEN1KDM4EPDE10A | |
| SCHEMBL23722878 | 0.86 | MOK (0.76) | MOKKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL23722872 | 0.83 | HTT (0.75) | MOKKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL19475285 | 0.82 | MOK (1.00) | MOKKMT2AMEN1KDM4EPDE10A | |
| SCHEMBL23722912 | 0.81 | MOK (0.68) | MOKKMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL19475498 | 0.81 | KMT2A (0.85) | MOKKMT2AMEN1KDM4EPDE10A | |
| SCHEMBL5154506 | 0.81 | KDM4E (1.00) | MOKKMT2AMEN1KDM4EPDE10A | |
| SCHEMBL19508993 | 0.80 | MOK (0.70) | MOKKMT2AMEN1KDM4EPDE10A | |
| SCHEMBL24449147 | 0.80 | MOK (0.66) | MOKKMT2AMEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | UNIV NEW YORK (US) | 2019-06-27 | — | — | US | claimed |
| WO-2017184547-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2017-10-26 | — | — | WO | claimed |
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | UNIV NEW YORK (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | UNIV NEW YORK (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | UNIV NEW YORK (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | UNIV NEW YORK (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017184547-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184547-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | AGER, HMGB1, GPR119 | MOK 4420/4885KMT2A 3436/4885MEN1 3331/4885 |
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | AGER, HMGB1, GPR119 | MOK 4420/4885KMT2A 3436/4885MEN1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.